Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT06282159 | A Phase 2 Study to Evaluate DNTH103 in Adults With Generalized Myasthenia Gravis (MAGIC) | PHASE2 | ACTIVE NOT_RECRUITING | 65 | — | — | Feb 23, 2024 | Oct 1, 2028 | Jun 8, 2026 | 56 | United States, Argentina +12 |
Number of participants with TEAEs and treatment-emergent SAEs will be reported.
| Arm | Type | Description |
|---|---|---|
| Placebo | PLACEBO_COMPARATOR | - |
| Claseprubart 300 mg Q2W | EXPERIMENTAL | - |
| Claseprubart 600 mg Q2W | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| Claseprubart | DRUG | Day 1: IV loading dose Week 1 to Week 11: Claseprubart administered SC every 2 weeks |
| Placebo | DRUG | Day 1: IV infusion of placebo Week 1 to Week 11: placebo administered SC every 2 weeks |
Inclusion Criteria: 1. Must have given written informed consent before any study-related activities are carried out. 2. Adult males and females, 18 to 75 years of age (inclusive) at Screening. 3. Weight range between 40-120 kg at Screening. 4. Diagnosis of gMG by the following tests: Acetylchol...